HIKAL234.10

Hikal Limited

· Pharma & Health
₹ CrorePeersPANACEABIODCALSAIPARENTINDOCOSOLARAWINDLASINDSWFTLABHESTERBIOMcap ₹2,891 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.730.730.620.58
Interest Burden (Pretax/EBIT) ×0.640.64-1.38-0.89
EBIT Margin %8.3710.433.303.76
Asset Turnover ×0.720.740.720.72
Financial Leverage (Assets/Equity) ×2.092.001.971.97
ROE (5-step product) %5.887.24-4.05-2.77
ROE (reported, avg-equity basis) %5.867.19-4.07-4.07
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.